Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc.
Since its acquisition by MHD in 2011, MLS has become one of the largest independent anatomic pathology labs in the United States. The Company provides subspecialty anatomic pathology services in the fields of gastroenterology, dermatology, hematology, breast health, and urology. Miraca Life Sciences has established a leading reputation among clinicians by creating an innovative, best-in-class practice that results in improved patient care. MLS’s skilled pathologists currently serve over 3,000 physicians and 5,500 patients each day, leveraging the Company’s state-of-the-art laboratory infrastructure and rigorous quality assurance practices.
David Burgstahler, President and Co-Managing Partner of Avista Capital Partners, said, “We are pleased to partner with MLS, a company that has truly distinguished itself as a market leader in anatomic pathology services. We look forward to supporting the Company’s development and expansion, and leveraging Avista’s deep expertise in the healthcare services sector.”
Charles Harwood, Healthcare Industry Executive at Avista, said, “MLS has established a reputation for excellence in its diagnostic precision and laboratory processes. We are excited to finance and guide the Company’s next phase of growth.”
Shigekazu Takeuchi, President and Group CEO at MHD, said, “We are really excited about a strategic partnership with Avista for the future growth of MLS. I do believe that MLS will achieve a quantum leap under Avista’s leadership and expertise in the US healthcare industry.”
Goldman, Sachs & Co. LLC acted as financial advisor and Skadden, Arps, Meagher & Flom LLP acted as legal counsel to MHD. Kirkland & Ellis LLP acted as legal counsel to Avista.
Presented by Avista Capital Partners, September 22, 2017